First Sale: 2026-03-11

Security Type(s): Equity, An interest in 50% of proceeds received (after deducting fees) from the potential future sale of a Rare Pediatric Disease Priority Review Voucher, to the extent received from the U.S. FDA in connection with the Company's laromestrocel program for HLHS.

Offer Amount: $33,515,000

Amount Sold: $15,890,000

Remaining: $17,625,000

First Sale: 2024-07-19

Offer Amount: $9,508,010

Remaining: $9,508,010

First Sale: 2024-06-18

Offer Amount: $9,444,516

Remaining: $9,444,516

First Sale: 2024-04-18

Offer Amount: $12,424,674

Remaining: $12,424,674

First Sale: 2023-12-22

Offer Amount: $2,571,942

Remaining: $2,571,942

First Sale: 2023-10-13

Offer Amount: $8,350,001

Remaining: $8,350,001

First Sale: 2021-12-03

Security Type(s): Equity

Offer Amount: $20,462,545

Amount Sold: $20,462,545

First Sale: 2020-01-22

Security Type(s): Equity

Offer Amount: $25,000,000

Amount Sold: $100,000

Remaining: $24,900,000

First Sale: 2017-10-20

Security Type(s): Equity

Offer Amount: $25,000,000

Amount Sold: $954,970

Remaining: $24,045,030